GLP 1 and Other Incretin Analogues Assoc Professor Samantha Hocking

About this episode

GLP 1 and Other Incretin Analogues Assoc Professor Samantha Hocking In this lecture, Sam Hocking focuses on incretin-based therapies for managing cardiometabolic diseases, particularly obesity and type 2 diabetes. He discusses the roles of GLP-1 and GIP in insulin regulation and appetite control, and highlights their potential beyond diabetes, including benefits for heart failure and chronic kidney disease. Hocking evaluates the effectiveness of agents like semaglutide and tizepatide, showcasing significant improvements in glycemic control and weight loss from clinical trials. He also addresses the cardiovascular benefits of these therapies, alongside practical considerations for clinicians in managing side effects and economic accessibility. The lecture concludes with a call for the clinical application of incretin therapies to enhance patient health outcomes. ------------------------------------------------------------------------------- If you are a General Practitioner who gets invited to dozens of webinars a month. The General Practice Clinical Sessions Podcast is designed for you. Instead of giving up an evening with your family for a live webinar or your weekend for a c